UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: September 14, 2015
(Date of earliest event reported)
VBI VACCINES INC.
(Exact name of registrant as specified in its charter)
|
Delaware (State or other jurisdiction of incorporation) |
0-18188 (Commission File Number) |
93-0589534 (IRS Employer Identification Number) |
|
222 3rd Street, Suite 2241 Cambridge, Massachusetts (Address of principal executive offices) |
|
02142 (Zip Code) |
(617) 830-3031
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective September 8, 2015, the board of directors of VBI Vaccines Inc. (the “Company”) appointed David E. Anderson as the Company’s Chief Scientific Officer.
Dr. Anderson, age 45, joined the Company full time as Vice President of Immunology in 2009 from Harvard Medical School, where he held a position as Assistant Professor. Prior to his appointment as Chief Scientific Officer, Dr. Anderson served as the Company’s Vice President of Research and most recently as Senior Vice President, Research, since July 2014.
The Employment Agreement, effective as of July 25, 2014, between Dr. Anderson and the Company (the “Anderson Employment Agreement”), the material terms of which are summarized on page 6 of the Company’s Current Report on Form 8-K under Item 5.02 filed on July 28, 2014, to which the Anderson Employment Agreement is attached as an exhibit, remains in effect without modification.
Dr. Anderson does not have any family relationships with any of the officers or directors of the Company.
Dr. Anderson does not have an interest in any transaction required to be reported pursuant to Item 404(a) of Regulation S-K under Securities Act of 1933, as amended.
|
Item 7.01 |
Regulation FD Disclosure. |
On January 30, 2015, the Company issued a press release announcing Dr. Anderson’s appointment as the Company’s Chief Scientific Officer. A copy of the press release is attached herewith as Exhibit 99.1.
The foregoing information under this Item 7.01 (including the exhibit hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
|
Item 9.01 |
Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated September 14, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 14, 2015
|
|
VBI VACCINES INC. |
| |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Jeff Baxter |
|
|
|
|
Jeff Baxter |
|
|
|
|
Chief Executive Officer |
|
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated September 14, 2015 |
Exhibit 99.1
VBI Vaccines Promotes Dr. David E. Anderson to Chief Scientific Officer
CAMBRIDGE, MA (September 14, 2015) – VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”) is pleased to announce the promotion of Dr. David E. Anderson, Ph.D., to Chief Scientific Officer. Dr. Anderson has led VBI’s research and development activities since he joined the company full time in 2009 from Harvard Medical School, where he served as a member of the faculty.
While at Harvard, Dr. Anderson participated in the development of a multi-disciplinary research program focused on elucidating mechanisms by which inflammation is regulated within the central nervous system, with relevance to a variety of human neurodegenerative diseases, including brain tumors, multiple sclerosis, and Alzheimer’s disease.
Prior to joining Harvard’s faculty, Dr. Anderson was a research immunologist at the University of California, Davis, where he developed an independent research program focused on immunity directed against malignant brain tumors. Dr. Anderson holds a Ph.D. from Harvard University and a B.S. from the University of California, Davis.
"Dr. Anderson is a dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity, and tumor immunology. He brings to VBI an outstanding track record of relevant professional achievements and a strong background in building and leading research teams,” said Jeff Baxter, VBI’s President and CEO. “David is an inventor of much of VBI’s intellectual property and actively manages its ongoing expansion. His deep domain experience and sound judgment will be invaluable as we advance our mission of developing innovative prophylactic and therapeutic vaccine candidates."
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus. VBI’s lead eVLP asset is a prophylactic Cytomegalovirus (“CMV”) vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. VBI’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.
Website Home: http://www.vbivaccines.com/
News and Insights: http://www.vbivaccines.com/wire/
Investors: http://ir.vbivaccines.com/
Company Contact
Perri Maduri, Communications Executive
Phone: (617) 830-3031 x124
Email: ir@vbivaccines.com
|
VBI Vaccines Inc. | 222 Third Street, Suite 2241 | Cambridge, MA 02142 | 617-830-3031 | info@vbivaccines.com |
1 |
Investor Contacts
Robert B. Prag, President
The Del Mar Consulting Group, Inc.
Phone: (858) 361-1786
Email: bprag@delmarconsulting.com
Scott Wilfong, President
Alex Partners, LLC
Phone: (425) 242-0891
Email: scott@alexpartnersllc.com
Forward-Looking Statement Disclosure
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of VBI. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to VBI cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, VBI will not obtain appropriate or necessary governmental approvals to market these or other potential products, VBI may not be able to obtain anticipated funding for its development projects or other needed funding, and VBI may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and VBI does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
More detailed information about VBI and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in VBI’s filings with the Securities and Exchange Commission (the “Commission”). VBI urges investors and security holders to read those documents free of charge at the Commission’s Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from VBI. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, VBI undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
|
VBI Vaccines Inc. | 222 Third Street, Suite 2241 | Cambridge, MA 02142 | 617-830-3031 | info@vbivaccines.com |
2 |